By Brittany Effross, Director, Implementation
I recently had the privilege of moderating a panel discussion at the Launch Excellence Summit in Boston, focused on a topic that is near and dear to me: what it takes to build a commercial launch engine that drives awareness, adoption, and growth for therapy launches.
As a pharmacist, I began my career working directly with patients and families navigating some of the most complex and challenging healthcare journeys imaginable. I saw firsthand the impact that delays in diagnosis, access barriers and fragmented care can have on people waiting for treatment. Today, in my role supporting rare disease launches, I’ve gained a different perspective, helping manufacturers prepare for the moment a therapy becomes available and ensuring the infrastructure is in place to support patients from day one.
Those experiences have shown me that a successful launch is about far more than commercialization. In rare disease, every launch represents the possibility of a life-changing treatment reaching patients who may have spent years searching for answers. When launch planning is done well, patients gain faster access to therapy, providers receive the support they need, and manufacturers are better equipped to deliver on the promise of innovation.
That’s why the panel topic resonated so strongly with me. The decisions made during development and launch planning have real-world implications for patients and families, making thoughtful collaboration across manufacturers, market access teams, patient support programs and specialty pharmacies essential to success. As specialty pharmacies operate at the intersection of patients, providers, manufacturers and payers, they offer unique insight into access barriers and patient needs.
The discussion brought together experienced commercial leaders who have successfully launched therapies or are preparing for upcoming launches. We explored everything from launch team structure and early planning to market access, operational flexibility and the growing role of AI in commercialization.
As I listened to the conversation, one theme kept resurfacing: successful rare disease launches begin long before FDA approval and require organizations to anticipate the realities of a small, highly complex patient population. In rare disease, success often comes down to how well organizations adapt to the realities of a small and complex patient population once launch begins.
Most importantly, these efforts are strengthened when all key stakeholders, including specialty pharmacy, are engaged from the beginning and equipped to respond to evolving patient needs.
As I reflected on the discussion afterward, I found myself taking away several valuable operational, stakeholder engagement and technology deployment insights.
Operational insights: Launches begin earlier than many organizations think
- Rare disease launches differ significantly from therapies targeting larger patient populations. They are uniquely complex, requiring organizations to support small, highly specialized patient populations, possess deep expertise in the patient journey and navigate challenging access pathways.
- Organizations that underestimate these complexities often find themselves reacting to challenges that could have been anticipated earlier through broader stakeholder engagement and deeper patient journey mapping.
- Flexibility is just as important as planning. Panelists noted that successful launches require the ability to adjust as market dynamics, stakeholder needs, and access barriers change.
Stakeholder engagement: Breaking down barriers through partnership
- While securing payer coverage is critical, the panel highlighted that true access involves much more than formulary placement. Patients must be able to navigate prior authorizations, financial assistance requirements, and care coordination processes that often create significant barriers to treatment initiation.
Technology is powerful, but partnership is essential
- The conversation also explored how AI, predictive analytics and advanced data tools are changing market segmentation and customer targeting.
- The most successful launches combine advanced technology with strong partnerships among manufacturers, specialty pharmacies, providers and patient support teams. When insights are paired with collaboration, organizations can translate data into meaningful action that helps patients access therapy faster and more seamlessly.
The patient must remain the focus
As the discussion concluded, I asked each panelist to share a final takeaway. While their perspectives varied, many returned to a common idea: the patient must remain at the center of every launch decision.
I could not agree more.
In rare disease, new therapies represent hope for patients and families who may have spent years searching for answers, navigating obstacles and waiting for an effective treatment option.
The organizations that keep that reality at the forefront of their planning and ongoing care delivery are often the ones best positioned for success.
Final thoughts
Moderating this discussion reinforced something I’ve seen throughout my career: successful rare disease launches are built around the realities of the patient journey.
For manufacturers preparing for their next launch, my advice is simple: bring specialty pharmacy into the conversation early. The insights gained can help bridge the gap between launch strategy and patient reality, ensuring that innovative therapies reach the people who need them as efficiently and effectively as possible.